| [1] |
ZENG Lijie, WANG Liang, YANG Lei .
Clinical features and treatment efficacy analysis of central nervous system involvement in extranodal nasal-type natural killer/T-cell lymphoma
[J]. Chinese Journal of Oncology Prevention and Treatment, 2025, 17(1): 81-87.
|
| [2] |
WU Jialu, GE Xia, CHEN Wenming, YANG Guangzhong.
Current status and progress of CAR-T cell therapy in multiple myeloma
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(5): 525-531.
|
| [3] |
LI Mengjiao, CEN Yali, DOU Baitao, SHU Rou, LI Yanling, QIU Ling, REN Shihui, YAO Hao, FAN Fangyi.
Advances in the application of molecular targeted drugs combined with CAR-T cell therapy in lymphoma
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(5): 532-539.
|
| [4] |
WANG Huijuan, CHEN Wenming, GENG Chuanying, YANG Guangzhong .
Clinical characteristics of patients with relapsed/refractory multiple myeloma after CAR-T cell therapy
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(5): 549-553.
|
| [5] |
LYU Liwei, CONG Jia, WU Yiping, WANG Liang .
BCMA CAR-T cell therapy for relapsed/refractory plasmablastic lymphoma: case report and clinical implication
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(5): 562-565.
|
| [6] |
BI Jianghan, ZHANG Yan, WANG Wei .
Glofitamab therapy under the dual challenge of novel coronavirus infection and CAR-T resistance: a case report of refractory diffuse large B-cell lymphoma
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(5): 566-570.
|
| [7] |
HE Ying, LI Mengjiao, CEN Yali, DOU Baitao, SHU Rou, LI Yanling, YAO Hao, FAN Fangyi.
CD19 CAR T-cell therapy: a case of refractory primary central nervous system diffuse large B-cell lymphoma
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(5): 571-576.
|
| [8] |
XIAO Xiaoyinan, WANG Ruikun, HAN Meng, LIU Sihan, ZHUO Fangqi, CHEN Minkuan, DU Yimeng, CHE Yongsheng, XU Xiaojie.
Construction of recombinant plasmid of AGK gene promoter and its transcriptional activity in T lymphocyte leukemia
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(5): 586-592.
|
| [9] |
LI Yixue, LI Yajun, Zeng Ruolan, HE Yizi, WANG Caiqin, XIAO Ling, ZHOU Hui.
Current status of CAR-T therapy for multiple myeloma: Challenges and hopes coexist
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(4): 392-398.
|
| [10] |
XIAO Wanting, ZHANG Chunyan, TIAN Biao, GAO Yaya, GAO Guangxun.
A novel immunotherapy strategy for relapsed/refractory multiple myeloma: GPRC5D bispecific antibody
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(4): 399-404.
|
| [11] |
LIANG Yuanzheng, WANG Henan, WANG Liang.
Effects of PPP2R5C on proliferation, apoptosis, and drug sensitivity of multiple myeloma cells
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(4): 405-411.
|
| [12] |
ZHOU Da, WANG Mingyue, LI Zhe, HE Qing, CEN Hong.
Single-center clinical experience of daratumumab combined with bendamustine in the treatment of multiple myeloma patients with secondary extramedullary disease
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(4): 412-416.
|
| [13] |
YANG Lei, ZENG Lijie, TAO Jianhua, YAO Na, CONG Jia, YANG Jing, WANG Henan, WEI Liqiang, WANG Liang.
Clinical analysis of extranodal NK/T-cell lymphoma,nasal type,manifesting with primary ocular lesions
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(3): 321-326.
|
| [14] |
LIU Yue, QI Shunan, LI Yexiong.
Application of PD-1/PD-L1 inhibitors in extranodal natural killer/T-cell lymphoma
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(3): 346-353.
|
| [15] |
YAO Qingchun, WU Longjunyu, YE Chunhua, LI Yuandong, ZHANG Chunyan.
Metabolic level of serum acetyl-carnitine in esophageal squamous cell carcinoma and its diagnostic value
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(2): 198-204.
|
